Search

What inspires the outstanding young scientists who come from around the world to train at MSK?

… Thursday, September 11, 2025 Their stories are all different — the daughter of farmers in rural China, the first scientist in a family of English professors, the child from a small town in Italy who never stopped asking “Why?” But one thing unites them: They left behind family and friends, their familiar

… Wednesday, September 28, 2022 Alexis Lopez is a self-described “MSK baby,” due to the 23-year career he’s built at Memorial Sloan Kettering Cancer Center (MSK), as well as the three decades his mother, Amarilis, served as a patient financial representative at MSK before retiring in 2014. “MSK has always

Memorial Sloan Kettering researchers say a drug that acts on noncancerous, tumor-infiltrating cells might provide a new treatment option for the most common and aggressive type of brain cancer.

… Tuesday, October 15, 2013 Summary Memorial Sloan Kettering researchers say a drug that acts on noncancerous, tumor-infiltrating cells might provide a new treatment option for the most common and aggressive type of brain cancer. White blood cells called macrophages patrol almost every tissue of the body

Learn how MSK researchers are trying to understand how the immune system senses cancer in order to make better immunotherapies.

… Friday, March 14, 2025 One way our immune system protects us is by ridding our bodies of altered cells that could lead to cancer. But exactly how and when does our immune system sense cancer? How do tumors evolve to avoid being detected? And how can a better understanding of this process help develop

Read about some of the most important clinical advances made at MSK in 2020.

… Monday, December 21, 2020 In 2020, Memorial Sloan Kettering clinical researchers continued to make major discoveries that will improve the treatment of cancer and guide the development of new therapies. Many of these studies were made possible by philanthropic donations, which allow researchers to pursue

Dr. Rudensky studies the development of white blood cells called T lymphocytes, which participate in the immune system response to infection. He joined the Sloan Kettering Institute in 2009.

… Wednesday, September 26, 2012 Summary Dr. Rudensky studies the development of white blood cells called T lymphocytes, which participate in the immune system response to infection. He joined the Sloan Kettering Institute in 2009. Alexander Y. Rudensky has been appointed the new Chair of the Immunology

Leukemia patients may do better on CAR T cell therapy when they are treated early, before their disease relapses.

… Monday, April 3, 2017 Summary For patients with leukemia who relapse after chemotherapy, treatment options have traditionally been limited. At MSK, an experimental immunotherapy called CAR T therapy has expanded options for these patients. New research data presented at this year’s annual meeting of

Evidence from a recent study, led by MSK urologic surgeon, Behfar Ehdaie, MD, MPH, indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later treatment is required.

… Friday, October 25, 2024 Growing evidence indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later treatment is required. For the past five years, a team of MSK researchers has

Learn more from Andrea Cercek about a new study showing that colorectal cancer rates are increasing in younger people.

… Tuesday, February 28, 2017 Summary MSK expert Andrea Cercek discusses findings from a new study showing rising colorectal cancer rates among people in their 20s and 30s. Though the overall incidence of colorectal cancer has been on the decline in the US for years, it is increasing among individuals in

Read about a new CAR T cell therapy now approved for marginal zone lymphoma (MZL).

… Friday, December 12, 2025 Marginal zone lymphoma is a slow-growing, rare form of  non-Hodgkin lymphoma that usually responds well to initial therapies. But in some patients, the disease keeps returning despite multiple treatments. Now the U.S. Food and Drug Administration (FDA) has approved a new therapy